Skip to Content

Rigel Pharmaceuticals Inc

Rating as of

Company Profile

Business Description

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken over all responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes Fostamatinib - ITP, Fostamatinib - AIHA, Fostamatinib - IgAN, BGB324 - Oral AXL Inhibitor, ATI-50001 & 50002 - JAK Inhibitors, DS-3032-MDM2 Inhibitor, THF-beta Inhibitors and AZD0449- Inhaled JAK Inhibitor.

Contact
1180 Veterans Boulevard
South San Francisco, CA, 94080
T +1 650 624-1100
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 163